Preview

Кардиология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Маркеры фиброза сосудистой стенки ММП-9 и TIMP-1 у пациентов с ишемической болезнью сердца в сочетании с сахарным диабетом 2го типа и без него

https://doi.org/10.18087/cardio.2019.5.10258

Полный текст:

Аннотация

Распространенность ишемической болезни сердца (ИБС) и сахарного диабета (СД) 2го типа в мире и в Российской Федерации постоянно увеличивается. В связи с этим продолжается изучение механизмов патогенеза обоих заболеваний для профилактики осложнений и смерти. СД 2го типа вносит ощутимый вклад в прогрессирование течения ИБС. Одним из общих патогенетических звеньев обоих заболеваний является развитие выраженного фиброза сосудистой стенки. В статье представлен анализ исследований, посвященных определению роли металлопротеиназы-9 (ММП-9) и тканевого ингибитора матриксных метал лопротеиназ (TIMP-1) в формировании фиброза сосудистой стенки.  

Об авторах

Ю. Н. Беленков
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)
Россия
Москва


Е. В. Привалова
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)
Россия
Москва


А. О. Юсупова
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)
Россия
Москва


А. В. Жито
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)
Россия
Москва


Список литературы

1. World Health Organization. WHO: Russian Federation. Statistics. [Интернет] Available at: http://www.who.int/countries/rus/en/

2. World Health Organization. WHO: Global report on diabetes. [Интернет] 2016. Available at: http://www.who.int/diabetes/global-report/en/

3. Дедов И. И., Шестакова М. В., Викулова О. К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;20(1):13–41

4. Haffner SM. Cardiovascular risk factors and the prediabetic syndrome. Annals of Medicine. 1996;28(4):363–70. PMID: 8862692

5. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28(12):2901–7. PMID: 16306552

6. Wannamethee SG. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90(12):1398–403. DOI: 10.1136/hrt.2003.026104

7. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8. DOI: 10.1136/bmj.38678.389583.7C

8. Visse R, Nagase H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry. Circulation Research. 2003;92(8):827–39. DOI: 10.1161/01.RES.0000070112.80711.3D

9. Persic V, Bastiancic AL, Rosovic I, Raljevic D, Samsa DT, Bastiancic L et al. Correlation between immunological-inflammatory markers and endothelial disfunction in the early stage of coronary heart disease. Medical Hypotheses. 2018;115:72–6. DOI: 10.1016/j.mehy.2018.04.001

10. Lahdentausta L, Leskela J, Winkelmann A, Tervahartiala T, Sorsa T, Pesonen E et al. Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence. Journal of Cardiovascular Translational Research. 2018;11(3):210– 20. DOI: 10.1007/s12265-018-9789-x

11. Newby AC. Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture. Physiological Reviews. 2005;85(1):1–31. DOI: 10.1152/physrev.00048.2003

12. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 1995;91(8):2125–31. PMID: 7697840

13. Cimmino G, Ragni M, Cirillo P, Petrillo G, Loffredo F, Chiariello M et al. C-reactive protein induces expression of matrix metalloproteinase9: A possible link between inflammation and plaque rupture. International Journal of Cardiology. 2013;168(2):981–6. DOI: 10.1016/j.ijcard.2012.10.040

14. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M et al. Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. Journal Of Investigative Medicine. 2003;51(5):295–300. DOI: 10.2310/6650.2003.3563

15. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease. Circulation. 2003;107(12):1579–85. DOI: 10.1161/01.CIR.0000058700.41738.12

16. Mirhafez SR, Avan A, Tajfard M, Mohammadi S, Moohebati M, Fallah A et al. Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease. Journal of Clinical Laboratory Analysis. 2017;31(5):e22100. DOI: 10.1002/jcla.22100

17. Yang DJ, Lee M-S, Kim WH, Park HW, Kim K-H, Kwon T-G et al. The impact of glucose control on coronary plaque composition in patients with diabetes mellitus. The Journal of Invasive Cardiology. 2013;25(3):137–41. PMID: 23468443

18. Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation. 2002;62(5):337–42. DOI: 10.1080/00365510260296483

19. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology. 1998;32(2):368–72. PMID: 9708462

20. Weihrauch D, Lohr NL, Mraovic B, Ludwig LM, Chilian WM, Pagel PS et al. Chronic Hyperglycemia Attenuates Coronary Collateral Development and Impairs Proliferative Properties of Myocardial Interstitial Fluid by Production of Angiostatin. Circulation. 2004;109(19):2343–8. DOI: 10.1161/01.CIR.0000129225.67353.1F

21. Mahajan N, Malik N, Bahl A, Sharma Y, Dhawan V. Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. Molecular and Cellular Biochemistry. 2009;330(1–2):201–9. DOI: 10.1007/s11010-009-0134-1

22. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris. Circulation. 2004;110(13):1747–53. DOI: 10.1161/01.CIR.0000142664.18739.92

23. Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, Nohara A et al. Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis. Clinical Chemistry and Laboratory Medicine. 2001;39(5):380–4. DOI: 10.1515/CCLM.2001.060

24. Fitzsimmons PJ, Forough R, Lawrence ME, Gantt DS, Rajab MH, Kim H et al. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis. 2007;194(1):196–203. DOI: 10.1016/j.atherosclerosis.2006.07.027

25. Tanindi A, Sahinarslan A, Elbeg S, Cemri M. Association of matrix metalloproteinase-1, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1, and interleukin-6 with epicardial and myocardial perfusion: Coronary Artery Disease. 2011;22(4):253– 8. DOI: 10.1097/MCA.0b013e328343fc18

26. Arsenault BJ, Kohli P, Lambert G, DeMicco DA, Laskey R, Messig MM et al. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology. 2016;118(4):494–8. DOI: 10.1016/j.amjcard.2016.05.044

27. Ceron CS, Luizon MR. Plasma matrix metalloproteinases in coronary artery disease patients. European Journal of Clinical Investigation. 2016;46(1):104–5. DOI: 10.1111/eci.12537

28. Macarie RD, Vadana M, Ciortan L, Tucureanu MM, Ciobanu A, Vinereanu D et al. The expression of MMP‐1 and MMP‐9 is upregulated by smooth muscle cells after their cross‐talk with macrophages in high glucose conditions. Journal of Cellular and Molecular Medicine. 2018;22(9):4366–76. DOI: 10.1111/jcmm.13728

29. Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U. Regulation and involvement of matrix metalloproteinases in vascular diseases. Frontiers in Bioscience (Landmark Edition). 2016;21:89–118. PMID: 26709763

30. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(2):283–8. PMID: 12588772

31. Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Current Medicinal Chemistry. 2009;16(11):1349–54. PMID: 19355890

32. Beton O, Arslan S, Acar B, Ozbilum N, Berkan O. Association between MMP-3 and MMP-9 polymorphisms and coronary artery disease. Biomedical Reports. 2016;5(6):709–14. DOI: 10.3892/br.2016.782

33. Nakagawa P, Romero CA, Jiang X, D’Ambrosio M, Bordcoch G, Peterson EL et al. Ac-SDKP decreases mortality and cardiac rupture after acute myocardial infarction. PLOS ONE. 2018;13(1):e0190300. DOI: 10.1371/journal.pone.0190300


Для цитирования:


Беленков Ю.Н., Привалова Е.В., Юсупова А.О., Жито А.В. Маркеры фиброза сосудистой стенки ММП-9 и TIMP-1 у пациентов с ишемической болезнью сердца в сочетании с сахарным диабетом 2го типа и без него. Кардиология. 2019;59(5):61-66. https://doi.org/10.18087/cardio.2019.5.10258

For citation:


Belenkov Y.N., Privalova E.V., Iusupova A.O., Zhito A.V. Markers of Vascular Wall Fibrosis Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Ischemic Heart Disease with and without Concomitant Type-2 Diabetes Mellitus. Kardiologiia. 2019;59(5):61-66. (In Russ.) https://doi.org/10.18087/cardio.2019.5.10258

Просмотров: 168


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)